Ösophaguskarzinom Update

Nadja Niclauss; Alexandra M. König; Jacob Izbicki; Stefan Paul Mönig

doi:10.1055/s-0043-113906

Allgemein- und Viszeralchirurgie up2date, Table of Contents

Allgemein- und Viszeralchirurgie up2date 2017; 11(05): 461-479
DOI: 10.1055/s-0043-113906

Oberer Gastrointestinaltrakt

Georg Thieme Verlag KG Stuttgart · New York

Ösophaguskarzinom Update

Nadja Niclauss

,

Alexandra M. König

,

Jacob Izbicki

,

Stefan Paul Mönig

Abstract

All articles of this category

Das Ösophaguskarzinom weist trotz multimodaler Therapieansätze weiterhin nur geringe 5-Jahres-Überlebensraten von 15 – 25% auf. Angelehnt an die im Jahr 2015 publizierte S3-Leitlinie sowie die „ESMO Clinical Practice Guidelines“ stellen wir in diesem Artikel Diagnostik, Staging und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus dar.

Schlüsselwörter

oberer Gastrointestinaltrakt, Onkologie, Chemotherapie, Radiotherapie, maligne Erkrankung

Full Text

References

Literatur
1 Robert Koch-Institut. Zentrum für Krebsregisterdaten (ZfKD). Im Internet: http://www.rki.de/DE/Content/Gesundheitsmonitoring/Krebsregisterdaten/krebs_node.html Stand: 22.06.2017
2 Pennathur A, Gibson MK, Jobe BA. et al. Oesophageal carcinoma. Lancet 2013; 381: 400-412
3 Bollschweiler E, Wolfgarten E, Gutschow C. et al. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92: 549-555
4 Steevens J, Botterweck AA, Dirx MJ. et al. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol 2010; 22: 669-678
5 Siegel R, Naishadham D, Jemal A. Cancer Statistics 2013. CA Cancer J Clin 2013; 63: 11-30
6 Porschen R, Buck A, Fischbach W. et al. S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Oesophagus. Z Gastroenterol 2015; 53: 1288-1347
7 Lordick F, Mariette C, Haustermans K. et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27 (S5): v50-v57
8 Sharma P, Dent J, Armstrong D. et al. The development and validation of an endoscopic grading system for Barrettʼs esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392-1399
9 Kutup A, Link BC, Schurr G. et al. Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy 2007; 39: 715-719
10 Mönig SP, Zirbes TK, Schröder W. et al. Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. Am J Roentgenol 1999; 173: 365-367
11 Alakus H, Batur M, Schmidt M. et al. Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun 2010; 31: 532-538
12 Brierley JD, Gospodarowicz MK, Wittekind C. eds. TNM Classification of malignant Tumours. 8th ed. UICC – Global Cancer Control. Oxford, UK, Hoboken, NJ: John Wiley & Sons, Inc.; 2016
13 Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th edn, part II and III. Esophagus 2017; 14: 37-65
14 Siewert JR, Hölscher AH, Becker K. et al. [Cardia Cancer: attempt at a therapeutically relevant classification]. Chirurg 1987; 58: 25-32
15 Cao Y, Liao C, Tan A. et al. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 2009; 41: 751-757
16 Hodari A, Hammoud ZT, Borgi JF. et al. Assessment of morbidity and mortality after esophagectomy using a modified frailty index. Ann Thorac Surg 2013; 96: 1240-1245
17 Hölscher AH, Stahl M, Messmann H. et al. Die neue S3-Leitlinie zum Ösophaguskarzinom. Chirurg 2016; 87: 865-872
18 Omloo JM, Lagarde SM, Hulscher JB. et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg 2007; 246: 992-1000
19 Kutup A, Nentwich MF, Bollschweiler E. et al. What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy. Ann Surg 2014; 260: 1016-1022
20 Sasako M, Sano T, Yamamoto S. et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia of subcardia: a randomised controlled trial. Lancet Oncol 2006; 7: 644-651
21 Fuchs H, Hölscher AH, Leers J. et al. Long-term quality of life after surgery for adenocarcinoma of the esophagogastric junction: extended gastrectomy or transthoracic esophagectomy?. Gastric Cancer 2016; 19: 312-317
22 Biere SS, Van Berge Henegouwen MI, Maas KW. et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 2012; 379: 1887-1892
23 Reeh M, Mina S, Bockhorn M. et al. Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg 2012; 1406-1414
24 Siewert JR, Stein HJ, Böttcher K. Lymphadenektomie bei Tumoren des oberen Gastrointestinaltrakts. Chirurg 1996; 67: 877-888
25 Peyre CG, Hagen JA, DeMeester SR. et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248: 549-556
26 Koenig AM, Prenzel KL, Bogoevski D. et al. Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol 2009; 16: 454-462
27 Gaur P, Blackmon SH. Jejunal grafts conduits after esophagectomy. J Thorac Dis 2014; 6: 333-340
28 Luketich JD, Pennathur A, Awais O. et al. Outcomes after minimally invasive esophagectomy. Ann Surg 2012; 256: 95-103
29 Xiong WL, Li R, Lei HK. et al. Comparison of outcomes between minimally invasive oesophagectomy and open oesophagectomy for oesophageal cancer. ANZ J Surg 2017; 87: 165-170
30 Briez N, Piessen G, Bonnetain F. et al. Open versus laparoscopically-assisted oesophagectomy for cancer: a multicentre randomised controlled phase III trial – the MIRO trial. BMC Cancer 2011; 11: 310
31 Mariette C, Meunier B, Pezet D. et al. Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicenter, openlabel, randomized phase III controlled trial, the MIRO trial. 2015 ASCO Gastrointestinal Cancers Symposium. J Clin Oncol 2015; 33 (Suppl. 03) 5
32 Gockel I, Lorenz D. Die onkologische Ösophagusresektion und -rekonstruktion: Offen, Hybrid, MIC oder Robotik?. Chirurg 2017;
33 Avery KN, Metcalfe C, Berrisford R. et al. The feasibility of a randomized controlled trial of esophagectomy for esophageal cancer – the ROMIO (Randomized Oesophagectomy : Minimally Invasive or Open) study : protocol for a randomized controlled trial. Trials 2014; 15: 200
34 Luketich JD, Pennathur A, Franchetti Y. et al. Minimally invasive Esophagectomy; Results of a prospective phase II multicenter trial – the Eastern Cooperative Oncology Group (E2202) study. Ann Surg 2015; 261: 702-707
35 Van Hillegersberg R, Seesing MFJ, Brenkman HFJ. et al. Roboterassistierte minimal-invasive Ösophagektomie. Chirurg 2016; 87: 635-642
36 Van der Sluis PC, Ruurda JP, Verhage RJ. et al. Oncologic long-term results of robot-assisted minimally invasive thoraco-laparoscopic esophagectomy with two-field lymphadenectomy for esophageal cancer. Ann Surg Oncol 2015; 22: S1350-S1356
37 Van der Sluis PC, Ruurda JP, van der Horst S. et al. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial). Trials 2012; 13: 230
38 Park S, Hwang Y, Lee HJ. et al. Comparison of robot-assisted esophagectomy and thoracoscopic esophagectomy in esophageal squamous cell carcinoma. J Thorac Dis 2016; 8: 2853-2861
39 Mönig SP, Schiffmann LM. Resektion beim fortgeschrittenen Adenokarzinom des Magens und des Ösophagus. Chirurg 2016; 87: 398-405
40 Al-Batran SE, Homann N, Pauligk C. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 Trial. JAMA Oncol 2017;
41 Cunningham D, Allum WH, Stenning SP. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
42 Al-Batran SE, Hofheinz RD, Pauligk C. et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016; 17: 1697-1708
43 Al-Batran SE, Homann N, Schmalenberg H. et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): a multicenter, randomized phase 3 trial. J Clin Oncol 2017; 35: abstr. 4004
44 Van Hagen P, Hulshof MC, van Lanschot JJ. et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-2084
45 Shapiro J, van Lanschot JJ, Hulshof MC. et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015; 16: 1090-1098
46 Pöttgen C, Stuschke M. Radiotherapy versus surgery within multimodality protocols for esophageal cancer – a metaanalysis of the randomized trials. Cancer Treat Rev 2012; 38: 599-604
47 Hölscher AH, Bollschweiler E, Bogoevski D. et al. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer – a propensity score matched analysis. Eur J Cancer 2014; 50: 2950-2957
48 Chiu CH, Chao YK, Chang HK. et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome?. Ann Surg Oncol 2013; 30: 4245-4251
49 Markar S, Gronnier C, Duhamel A. et al. Salvage surgery after chemoradiotherapy in the management of esophageal cancer: Is it a viable therapeutic option?. J Clin Oncol 2015; 33: 3866-3873
50 Götze TO, Schiffman LM, Al-Batran SE. et al. Therapiekonzepte beim metastasierten Magenkarzinom. Allgemein- und Viszeralchirurgie up2date 2017; 11: 67-80
51 Webb A, Cunningham D, Scarffe JH. et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267
52 Al-Batran SE, Hartmann JT, Hofheinz R. et al. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2008; 19: 1882-1887
53 Bang YJ, Van Cutsem E, Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697
54 Kachaamy T, Pannala R. Esophageal stents: when and how. Minerva Gastroenterol Dietol 2016; 62: 155-166
55 Kondrup J, Allison SP, Elia M. et al. ESPEN guidelines for nutrition screening 2002. Clin Nutr 2003; 22: 415-421
56 Hennessey DB, Burke JP, Ni-Dhonochu T. et al. Preoperative hypoalbuminemia is an independent risk factor for the development of surgical site infection following gastrointestinal surgery: a multi-institutional study. Ann Surg 2010; 252: 325-329
57 Baiocchi GL, DʼUgo D, Coit D. et al. Follow-up after gastrectomy for cancer. The Charter Scaligero Consensus Conference. Gastric Cancer 2016; 19: 15-20